What you should know:
– Senseonics Holdings, Inc.a provider of implantable long-term continuous glucose monitoring (CGM) systems, today announced a strategic partnership with Rimidi. Rimidi offers a comprehensive clinical management platform designed to improve chronic disease management for patients and healthcare providers.
– The collaboration aims to develop the Eversense® Remote Patient Monitoring (RPM) Programwhich will integrate seamlessly with existing healthcare workflows.
Improving diabetes care with remote monitoring
The Eversense CGM + RPM solution will combine Senseonics’ long-lasting Eversense sensor with Rimidi’s user-friendly clinical management platform. Here’s how this partnership will benefit patients and providers:
- Streamlined data integration: Eversense glucose data will be seamlessly integrated into Rimidi’s platform, allowing it to be securely transferred to widely used electronic health records (EHR) systems. This allows healthcare providers to directly access a patient’s blood glucose data, eliminating the need for manual data entry.
- Improved patient engagement: The program aims to improve patient engagement by providing healthcare providers with tools to proactively monitor blood sugar trends, identify potential issues, and offer personalized guidance on blood sugar adjustments. lifestyle and medications.
- Improved clinical decisions: With increased visibility into patient data, healthcare providers can make more informed decisions regarding treatment plans, which could potentially lead to better diabetes management and clinical outcomes.
- Reduced healthcare costs: By enabling proactive care and potentially preventing complications, the Eversense CGM + RPM solution has the potential to reduce overall healthcare costs associated with diabetes management.
Partnership aligns with industry standards
Rimidi’s platform is designed to meet the requirements of Medicare’s reimbursable remote patient monitoring telehealth programs. It also integrates seamlessly with existing EHR systems, ensuring a smooth workflow for healthcare providers.
Gradual deployment and future availability
Senseonics, in collaboration with its commercial partner Ascensia Diabetes Care, plans a phased deployment of the Eversense CGM + RPM solution. The program will initially be made available to select population health-based systems in Q3 2024, with future expansion planned to all healthcare providers and Eversense users.
“We are excited to combine our clinical management platform with Senseonics technology. Our platform and its capabilities were designed to leverage data from medical devices like Eversense CGM to streamline and improve chronic disease management,” said Lucienne Ide, MD, PhD, Chief Executive Officer of Rimidi. “81% of patients with type 2 diabetes do not meet their HbA1c, blood pressure and cholesterol goals, and this partnership represents an exciting opportunity to help providers improve blood sugar outcomes for this population. »
